Biosimilar alliance between Celerion and Ricerca

Biosimilars/News | Posted 09/03/2012 post-comment0 Post your comment

Contract research organisations (CROs) Celerion and Ricerca Biosciences announced on 29 February 2012 the formation of an integrated service solution for the development of biosimilar products.

picture30

The agreement between the two CROs, named ‘The Biosimilars Alliance’, aims to provide early assessment of the viability of candidate biosimilars before entering into costly clinical trials. These early assessment services will include in vitro and in vivo pharmacological assessments of activity and toxicological and immunotoxicological studies.

The alliance also aims to provide bioanalytical assay development to enable pharmacokinetic (PK) and pharmacodynamic (PD) assessments in animal and human studies, PK/PD modelling, immunogenicity screening during clinical studies and the regulatory and integrated project management support to ensure timely results for strategic decision-making.

The biosimilars business has been characterised by partnerships, which is not surprising considering that the costs of developing a typical biosimilar are estimated to be more than US$100 million and that they may take five to six years to develop–much more than a small molecule generic–reflecting the complexity of the molecules in question [1].

According to Celerion, the market for biosimilars is forecast to grow from US$2.4 billion in 2012 to US$44 billion by 2020, making it a lucrative market despite the costs.

Related articles

Baxter and Momenta make biosimilars deal

Amgen finally jumps on biosimilars bandwagon

Samsung makes biosimilars deal with Biogen Idec

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Partnerships will drive biosimilar development [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2012 Mar 9]. Available from: www.gabionline.net/Biosimilars/News/Partnerships-will-drive-biosimilar-development

Source: Celerion

comment icon Comments (0)
Post your comment
Related content
EC approval of first ustekinumab biosimilar Uzpruvo
IBD 1
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010